<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial
Mark J. Levis(Sidney Kimmel Cancer Center), Alexander E. Perl(University of Pennsylvania), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Arnaud Lesegretain(Daiichi Sankyo (United States)), Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), Elżbieta Patkowska(Institute for Transfusion Medicine), Jaime E. Connolly Rohrbach(Daiichi Sankyo (United States)), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Radovan Vrḫovac(University Hospital Centre Zagreb), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Liu(Shihezi University), Hee‐Je Kim(St. Mary's Hospital), Pavel Žák(University Hospital Hradec Králové), Hervé Dombret(University of London Institute in Paris), Ken C. N. Chang(Daiichi Sankyo (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 7
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k